Abstract
Increased sedation, somnolence, and sleep episodes seem to occur with several, if not all, dopamine agonists and dopaminergic treatment. Patients at risk of sleep episodes can be identified by well-chosen questions, and could be managed by appropriate measures including dose reduction.
MeSH terms
-
Antiparkinson Agents / adverse effects*
-
Antiparkinson Agents / therapeutic use
-
Dose-Response Relationship, Drug
-
Female
-
Humans
-
Male
-
Middle Aged
-
Narcolepsy / chemically induced*
-
Narcolepsy / diagnosis
-
Parkinson Disease / drug therapy*
-
Pergolide / adverse effects*
-
Pergolide / therapeutic use
Substances
-
Antiparkinson Agents
-
Pergolide